Dyne Therapeutics, INC Schedule 13G passive stakes

Atlas Venture Fund XI, L.P. and affiliated entities have reported a change in their beneficial ownership of Dyne Therapeutics, Inc. common stock, now holding a combined 3.6% stake.

Janus Henderson Group Ltd. has disclosed a beneficial ownership of 7.3% of Dyne Therapeutics Inc.'s common stock as of June 30, 2026.

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 6.8% of Dyne Therapeutics Inc.'s common stock as of June 30, 2026.

BlackRock, Inc. has filed a Schedule 13G, reporting beneficial ownership of 7.0% of Dyne Therapeutics, Inc. common stock as of June 30, 2026.

Janus Henderson Group plc has reported beneficial ownership of 13,647,376 shares of Dyne Therapeutics Inc. common stock, representing 8.3% of the class.

T. Rowe Price Investment Management, Inc. has reported a significant beneficial ownership stake of 18.7% in Dyne Therapeutics Inc., as of March 31, 2026.

FMR LLC has reported beneficial ownership of 5.4% of Dyne Therapeutics Inc.'s common stock as of March 31, 2026.

The Vanguard Group has amended its Schedule 13G filing for Dyne Therapeutics Inc., reporting zero beneficial ownership following an internal realignment.

T. Rowe Price Investment Management, Inc. reported an increased beneficial ownership of 16.2% in Dyne Therapeutics Inc. common stock.

T. Rowe Price Investment Management, Inc. has reported a significant 10.7% beneficial ownership stake in Dyne Therapeutics Inc. common stock as of December 31, 2025.

RA Capital Management and its affiliates have reported a complete divestment of their beneficial ownership in Dyne Therapeutics, Inc., holding 0.0% of common stock as of September 30, 2025.

Janus Henderson Group plc has increased its beneficial ownership in Dyne Therapeutics Inc. to 10.4% of common stock, holding 14,745,505 shares.

Atlas Venture and its affiliated funds collectively report a 6.4% beneficial ownership in Dyne Therapeutics, Inc. as of September 30, 2025.

Janus Henderson Group plc has filed an amended Schedule 13G, disclosing a beneficial ownership of 10.1% in Dyne Therapeutics Inc.'s common stock.

RA Capital Management, L.P. and its affiliates have disclosed a beneficial ownership of 8.5% in Dyne Therapeutics, Inc., holding 9,714,392 shares of common stock as of March 31, 2025.

Point72 Asset Management, along with its affiliates and Steven A. Cohen, has filed an amended Schedule 13G, reporting a passive beneficial ownership of 1.5% in Dyne Therapeutics, Inc. as of March 31, 2025.

Multiple Forbion-affiliated investment entities have filed an amended Schedule 13G, detailing their collective beneficial ownership in Dyne Therapeutics, Inc. common stock as of March 31, 2025.

RTW Investments, LP and its Managing Partner, Dr. Roderick Wong, have filed an amended Schedule 13G, reporting a beneficial ownership of 1.5% in Dyne Therapeutics, Inc.'s common stock as of March 31, 2025.

Investment manager Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 9.2% beneficial ownership stake in Dyne Therapeutics Inc.'s common stock.

FMR LLC, along with Abigail P. Johnson, has filed an amendment to their Schedule 13G, disclosing a 4.6% beneficial ownership stake in Dyne Therapeutics Inc. as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 5.8% passive beneficial ownership stake in Dyne Therapeutics, Inc. as of March 31, 2025.

Janus Henderson Group PLC has filed an amended Schedule 13G, revealing a 7.3% beneficial ownership stake in Dyne Therapeutics Inc. as of December 31, 2024.

RTW Investments, LP and its Managing Partner, Dr. Roderick Wong, have disclosed a 5.1% beneficial ownership stake in Dyne Therapeutics, Inc., holding 5,218,641 shares as of December 31, 2024.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 7.9% beneficial ownership stake in Dyne Therapeutics Inc. as of December 31, 2024.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, has disclosed a 5.1% beneficial ownership stake in Dyne Therapeutics, Inc., totaling 5,196,597 shares.